MorphoSys, the German biotech company, has delivered positive news to its shareholders. The Phase 3 myelofibrosis program is progressing 16%…
Browsing: MorphoSys
Roche’s Alzheimer’s drug Gantenerumab has experienced a major setback. It failed phase 3 clinical trials, resulting in financial losses for…
MorphoSys is on track to complete its Phase 3 myelofibrosis program 16% faster than originally planned. [1] However, there is…
MorphoSys is making significant strides in its Phase 3 myelofibrosis program, completing it 16% faster than expected [1]. This is…
MorphoSys, a leading biotechnology company, has recently announced updates to its Q2 and FY22 guidance levels. Revealing higher projections than…
MorphoSys, a German biopharmaceutical company, has reported its fourth-quarter financial results, showing signs of improvement and reaffirming its guidance for…
MorphoSys, the German biopharmaceutical company, has recently made a strategic decision to shift its focus from pre-clinical research to clinical-stage…